DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more



Characteristics and Management of Postmenopausal Women With Osteoporosis Treated With Prolia� in France

Information source: Amgen
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Post Menopausal Osteoporosis

Intervention: AMG 162 - Prolia (Drug); AMG 162 - Prolia (Drug)

Phase: N/A

Status: Recruiting

Sponsored by: Amgen

Official(s) and/or principal investigator(s):
MD, Study Director, Affiliation: Amgen

Overall contact:
Amgen Call Center, Phone: 866-572-6436

Summary

The purpose of the study is to describe the characteristics and management of post menopausal women with osteoporosis treated with Prolia in France, and examine the use of Prolia in routine clinical practice in France

Clinical Details

Official title: Prospective Observational Study to Describe Characteristics and Management of Postmenopausal Women With Osteoporosis Treated With Prolia in France and Its Use in Routine Clinical Practice

Study design: Observational Model: Case-Only, Time Perspective: Prospective

Primary outcome: patient occurence of persistence (persistence is defined in the outcome description) at 12 months

Secondary outcome:

patient occurence of persistence (persistence is defined in the outcome description) at 24 months and time to non-persistence at 24 months

describe the use of Prolia in routine clinical practice during approximately 30 months from the first injection

patient occurence of Adverse Drug Reactions (ADRs) and Serious Adverse Drug Reactions (SADRs) as collected in routine clinical practice

Occurrence of patient reported osteoporosis related vertebral and non vertebral fractures reported during the study

Detailed description: This is a multicenter, observational and non-interventional study in PMO patients who receive Prolia® (60 mg subcutaneous [SC]) in France. Patients in the study will be enrolled in 2 waves, each targeting specific aspects of the overall study objectives. The first wave will enroll approximately 500 patients who will be followed for approximately 30 months from the first injection. Patients enrolled in this wave will provide descriptive data on persistence to Prolia® as well as a description of the characteristics of patients being prescribed Prolia®, information regarding Prolia® prescription and administration, procedures pertaining to Prolia® and safety. The second wave will enroll approximately 250 patients and will only provide a cross-sectional description of the characteristics of patients being prescribed Prolia. Around 2000 specialists in rheumatology and 9000 general practitioners will be randomly selected from a list of rheumatologists whether in hospital or private practice nationwide and a list of general practitioners managing patients with osteoporosis. In all, 300 physicians initially interested to participate are expected, from which about 180 physicians will be qualified to participate. One-hundred and ten physicians will be initiated. There are no procedures or changes to the routine clinical management of patients participating in the study. Baseline characteristics will be described for patients enrolling in both waves 1 and 2. Patients enrolling in wave 1 will be followed for approximately 30 months from the date of first injection in the study. It is anticipated that patients will return to the site. Clinical information obtained for routine clinical practice will be recorded where available, including Prolia administration, previous and current therapies, medical history (including fracture), ADRs, SADRs and co-morbidities. The study is descriptive in nature, and no formal hypothesis will be tested. In general, data summaries will be presented by wave and by subgroups of interest.

Eligibility

Minimum age: 40 Years. Maximum age: 95 Years. Gender(s): Female.

Criteria:

Inclusion Criteria:

- post menopausal osteoporosis women in whom a decision has been made to treat with

Prolia in the last 4 weeks

- received their first prescription of Prolia in the last 4 weeks

- patient has provided informed consent before enrolling in the study

Exclusion Criteria:

- patients participating in ongoing or previous Denosumab clinical trials

Locations and Contacts

Amgen Call Center, Phone: 866-572-6436

Amgen, Paris 92200, France; Recruiting
Additional Information

AmgenTrials clinical trials website

Starting date: June 2015
Last updated: August 14, 2015

Page last updated: August 23, 2015

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017